Literature DB >> 25042474

Interim FDG PET/CT for predicting the outcome in patients with head and neck cancer.

Shang-Wen Chen1, Te-Chun Hsieh, Kuo-Yang Yen, Shih-Neng Yang, Yao-Ching Wang, Chun-Ru Chien, Ji-An Liang, Chia-Hung Kao.   

Abstract

OBJECTIVES/HYPOTHESIS: The study aimed to investigate the prognostic effects of interim (18) fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (PET/CT) during definitive radiotherapy (RT) or chemoradiotherapy (CRT) in patients with head and neck cancer. STUDY
DESIGN: This is a prospectively treatment study.
METHODS: The pretreatment and interim PET/CT images of 51 patients with advanced pharyngeal cancers receiving definitive RT/CRT were evaluated prospectively. The interim PET/CT images were taken at a cumulative RT dose ranging from 41.4 to 46.8 Gy. The maximum standardized uptake value (SUVm) of the interim PET/CT and the reduction ratio of the SUVm (SRR) between the two images were measured. The differences between patients with or without local failures were examined using the Mann-Whitney test. Overall survival (OS), disease-free survival (DFS), and primary and nodal relapse-free survival rates were calculated using the Kaplan-Meier method. Independent prognosticators were identified using Cox regression analysis.
RESULTS: After a median follow-up duration of 23 months, a higher interim SUVm was associated with local failures. Conducting a multivariate analysis revealed that a SUVmax reduction ratio of primary tumor (SRR-P) < 0.64 was associated with the inferior OS (hazard ratio 2.64; P =0.035) and DFS (hazard ratio 2.33; P = 0.045). Patients who had tumors with an SRR-P < 0.64 had a considerably lower 2-year OS and DFS compared with those who had SRR-P ≥ 0.64 (47% vs. 66%; 41% vs. 64%).
CONCLUSION: A higher interim SUVm was associated with local recurrence. In addition, patients with a lower SRR-P should be considered to be at risk of primary failure. LEVEL OF EVIDENCE: 4.
© 2014 The American Laryngological, Rhinological and Otological Society, Inc.

Entities:  

Keywords:  18Fluoro-2-deoxy-D-glucose; PET/CT; chemoradiotherapy; head and neck cancer; response marker

Mesh:

Substances:

Year:  2014        PMID: 25042474     DOI: 10.1002/lary.24826

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  10 in total

1.  PET-based prognostic survival model after radiotherapy for head and neck cancer.

Authors:  Joël Castelli; A Depeursinge; A Devillers; B Campillo-Gimenez; Y Dicente; J O Prior; E Chajon; F Jegoux; C Sire; O Acosta; E Gherga; X Sun; B De Bari; J Bourhis; R de Crevoisier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-21       Impact factor: 9.236

2.  Immunohistochemical overexpression of hypoxia-induced factor 1α associated with slow reduction in 18fluoro-2-deoxy-D-glucose uptake for chemoradiotherapy in patients with pharyngeal cancer.

Authors:  Shang-Wen Chen; Ying-Chun Lin; Rui-Yun Chen; Te-Chun Hsieh; Kuo-Yang Yen; Ji-An Liang; Shih-Neng Yang; Yao-Ching Wang; Ya-Huey Chen; Nan-Haw Chow; Chia-Hung Kao
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-06-16       Impact factor: 9.236

3.  Impact of PET/CT on Staging and Treatment of Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Jeffery B Jorgensen; Russell B Smith; Andrew Coughlin; William C Spanos; Michele M Lohr; Steven M Sperry; Oleg Militsakh; Robert P Zitsch; Bevan Yueh; Laura M Dooley; Aru Panwar; Tabitha L I Galloway; Nitin A Pagedar
Journal:  Otolaryngol Head Neck Surg       Date:  2018-08-21       Impact factor: 3.497

4.  Prognostic role of metabolic parameters of (18)F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma.

Authors:  Myo Min; Peter Lin; Mark T Lee; Ivan Ho Shon; Michael Lin; Dion Forstner; Victoria Bray; Andrew Chicco; Minh Thi Tieu; Allan Fowler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-06-17       Impact factor: 9.236

Review 5.  What is the prognostic impact of FDG PET in locally advanced head and neck squamous cell carcinoma treated with concomitant chemo-radiotherapy? A systematic review and meta-analysis.

Authors:  Pierluigi Bonomo; A Merlotti; E Olmetto; A Bianchi; I Desideri; A Bacigalupo; P Franco; C Franzese; E Orlandi; L Livi; S Caini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-09       Impact factor: 9.236

6.  Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients.

Authors:  Suzy Kim; Sowon Oh; Jin Soo Kim; Yu Kyeong Kim; Kwang Hyun Kim; Do Hoon Oh; Dong-Han Lee; Woo-Jin Jeong; Young Ho Jung
Journal:  Radiat Oncol J       Date:  2018-06-29

Review 7.  Optimized imaging of the midface and orbits.

Authors:  Sönke Langner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2015-12-22

8.  Is interim 18F-fluoride PET/CT a predictor of outcomes after radium-223 therapy?

Authors:  Elba Etchebehere; Ana Emília Brito; Kalevi Kairemo; Eric Rohren; John Araujo; Homer Macapinlac
Journal:  Radiol Bras       Date:  2019 Jan-Feb

Review 9.  Predicting response to radiotherapy in tumors with PET/CT: when and how?

Authors:  Li-Fang Shen; Shui-Hong Zhou; Qi Yu
Journal:  Transl Cancer Res       Date:  2020-04       Impact factor: 1.241

10.  End of treatment cone-beam computed tomography (CBCT) is predictive of radiation response and overall survival in oropharyngeal squamous cell carcinoma.

Authors:  Whitney Sumner; Sangwoo S Kim; Lucas Vitzthum; Kevin Moore; Todd Atwood; James Murphy; Sayuri Miyauchi; Joseph A Califano; Loren K Mell; Arno J Mundt; Andrew B Sharabi
Journal:  Radiat Oncol       Date:  2021-08-09       Impact factor: 3.481

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.